カテゴリー： Transparency Market Research, 世界, 医療/バイオ

心臓幹細胞の世界市場2023～2031：用途別、ソース別

◆英語タイトル：Cardiology Stem Cells Market (Application: Heart Failure, Myocardial Infarction, Critical Limb Ischemia, and Others; Source: Autologous and Allogenic) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031

Transparency Market Researchが発行した調査報告書（TMR23MA029）◆商品コード：TMR23MA029
◆発行会社（リサーチ会社）：Transparency Market Research
◆発行日：2023年3月2日
◆ページ数：158
◆レポート形式：英語 / PDF
◆納品方法：Eメール（受注後24時間以内）
◆調査対象地域：北米、中南米、ヨーロッパ、アジア太平洋、中東・アフリカ
◆産業分野：医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧）USD5,795 ⇒換算￥880,840見積依頼/購入/質問フォーム
Multi User（5名様閲覧）USD8,795 ⇒換算￥1,336,840見積依頼/購入/質問フォーム
Corporate License（法人閲覧）USD11,795 ⇒換算￥1,792,840見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

Transparency Market Research社の当調査レポートでは、世界の心臓幹細胞市場規模が、2023年の26億ドルから2031年に51億ドルとなり、予測期間中に年平均成長率7.4%で拡大すると展望しています。本書は、心臓幹細胞の世界市場にフォーカスし、市場状況や今後の動向などをまとめた資料です。序論、仮定・調査手法、エグゼクティブサマリー、市場概要、主要インサイト、細胞種類別（胚性幹細胞、成体幹細胞、人工多能性幹細胞、臍帯血幹細胞・羊水幹細胞）分析、用途別（心不全、心筋梗塞、重症虚血肢、その他）分析、ソース別（自家、同種）分析、エンドユーザー別（製薬・バイオテクノロジー企業、病院・細胞バンク、学術・研究機関）分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ）分析、競争状況など、以下の構成で掲載しています。また、市場参入企業として、Astellas Pharma, Inc.、STEMCELL Technologies、Cellular Engineering Technologies、BioTimes, Inc.、Takara Bio, Inc.、U.S. Stem Cell, Inc.、BrainStorm Cell Limited.、Cytori Therapeutics, Inc.、Lisata Therapeutics、Bio Cardia, Inc.などの情報が含まれています。
・序論
・仮定・調査手法
・エグゼクティブサマリー
・市場概要
・主要インサイト
・世界の心臓幹細胞市場規模：細胞種類別
- 胚性幹細胞における市場規模
- 成体幹細胞における市場規模
- 人工多能性幹細胞における市場規模
- 臍帯血幹細胞・羊水幹細胞における市場規模
・世界の心臓幹細胞市場規模：用途別
- 心不全における市場規模
- 心筋梗塞における市場規模
- 重症虚血肢における市場規模
- その他用途における市場規模
・世界の心臓幹細胞市場規模：ソース別
- 自家細胞の市場規模
- 同種細胞の市場規模
・世界の心臓幹細胞市場規模：エンドユーザー別
- 製薬・バイオテクノロジー企業における市場規模
- 病院・細胞バンクにおける市場規模
- 学術・研究機関における市場規模
・世界の心臓幹細胞市場規模：地域別
- 北米の心臓幹細胞市場規模
- ヨーロッパの心臓幹細胞市場規模
- アジア太平洋の心臓幹細胞市場規模
- 中南米の心臓幹細胞市場規模
- 中東・アフリカの心臓幹細胞市場規模
・競争状況

Cardiology Stem Cells Market – Scope of Report
TMR’s report on the global cardiology stem cells market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global cardiology stem cells market for the period 2017–2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global cardiology stem cells market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the cardiology stem cells market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global cardiology stem cells market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global cardiology stem cells market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global cardiology stem cells market.

The report delves into the competitive landscape of the global cardiology stem cells market. Key players operating in the global cardiology stem cells market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global cardiology stem cells market profiled in this report.

Key Questions Answered in Global Cardiology Stem Cells Market Report
• What is the sales/revenue generated by cardiology stem cells across all regions during the forecast period?
• What are the opportunities in the global cardiology stem cells market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2031?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?

Cardiology Stem Cells Market – Research Objectives and Research Approach
The comprehensive report on the global cardiology stem cells market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global cardiology stem cells market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global cardiology stem cells market.

❖ レポートの目次 ❖

1. Preface
    1.1. Market Definition and Scope
    1.2. Market Segmentation
    1.3. Key Research Objectives
    1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Cardiology Stem Cells Market
4. Market Overview
    4.1. Introduction
        4.1.1. Segment Definition
    4.2. Overview
    4.3. Market Dynamics
        4.3.1. Drivers
        4.3.2. Restraints
        4.3.3. Opportunities
    4.4. Global Cardiology Stem Cells Market Analysis and Forecast, 2017-2031
        4.4.1. Market Revenue Projections (US$ Bn)
5. Key Insights
    5.1. Key Mergers & Acquisitions
    5.2. COVID-19 Pandemic Impact on Industry (value chain and short / mid / long term impact)
    5.3. Pipeline Analysis
    5.4. Disease Prevalence & Incidence Rate globally with key countries
6. Global Cardiology Stem Cells Market Analysis and Forecast, by Type of Cell
    6.1. Introduction & Definition
    6.2. Key Findings / Developments
    6.3. Market Value Forecast, by Type of Cell, 2017-2031
        6.3.1. Embryonic Stem Cells
        6.3.2. Adult Stem Cells
        6.3.3. Induced Pluripotent Stem Cells
        6.3.4. Cord Blood Stem Cells and Amniotic Fluid Stem Cells
    6.4. Market Attractiveness Analysis, by Type of Cell
7. Global Cardiology Stem Cells Market Analysis and Forecast, by Application
    7.1. Introduction & Definition
    7.2. Key Findings / Developments
    7.3. Market Value Forecast, by Application, 2017-2031
        7.3.1. Heart Failure
        7.3.2. Myocardial Infarction
        7.3.3. Critical Limb Ischemia
        7.3.4. Others
    7.4. Market Attractiveness Analysis, by Application
8. Global Cardiology Stem Cells Market Analysis and Forecast, by Source
    8.1. Introduction & Definition
    8.2. Key Findings / Developments
    8.3. Market Value Forecast, by Source, 2017-2031
        8.3.1. Autologous
        8.3.2. Allogenic
    8.4. Market Attractiveness Analysis, by Source
9. Global Cardiology Stem Cells Market Analysis and Forecast, by End-user
    9.1. Introduction & Definition
    9.2. Key Findings / Developments
    9.3. Market Value Forecast, by End-user, 2017-2031
        9.3.1. Pharmaceutical & Biotechnology Companies
        9.3.2. Hospitals & Cell Banks
        9.3.3. Academic & Research Institutes
    9.4. Market Attractiveness Analysis, by End-user
10. Global Cardiology Stem Cells Market Analysis and Forecast, by Region
    10.1. Key Findings
    10.2. Market Value Forecast, by Region
        10.2.1. North America
        10.2.2. Europe
        10.2.3. Asia Pacific
        10.2.4. Latin America
        10.2.5. Middle East & Africa
    10.3. Market Attractiveness Analysis, by Region
11. North America Cardiology Stem Cells Market Analysis and Forecast
    11.1. Introduction
        11.1.1. Key Findings
    11.2. Market Value Forecast, by Type of Cell, 2017-2031
        11.2.1. Embryonic Stem Cells
        11.2.2. Adult Stem Cells
        11.2.3. Induced Pluripotent Stem Cells
        11.2.4. Cord Blood Stem Cells and Amniotic Fluid Stem Cells
    11.3. Market Value Forecast, by Application, 2017-2031
        11.3.1. Heart Failure
        11.3.2. Myocardial Infarction
        11.3.3. Critical Limb Ischemia
        11.3.4. Others
    11.4. Market Value Forecast, by Source, 2017-2031
        11.4.1. Autologous
        11.4.2. Allogenic
    11.5. Market Value Forecast, by End-user, 2017-2031
        11.5.1. Pharmaceutical & Biotechnology Companies
        11.5.2. Hospitals & Cell Banks
        11.5.3. Academic & Research Institutes
    11.6. Market Value Forecast, by Country, 2017-2031
        11.6.1. U.S.
        11.6.2. Canada
    11.7. Market Attractiveness Analysis
        11.7.1. By Type of Cell
        11.7.2. By Application
        11.7.3. By Source
        11.7.4. By End-user
        11.7.5. By Country
12. Europe Cardiology Stem Cells Market Analysis and Forecast
    12.1. Introduction
        12.1.1. Key Findings
    12.2. Market Value Forecast, by Type of Cell, 2017-2031
        12.2.1. Embryonic Stem Cells
        12.2.2. Adult Stem Cells
        12.2.3. Induced Pluripotent Stem Cells
        12.2.4. Cord Blood Stem Cells and Amniotic Fluid Stem Cells
    12.3. Market Value Forecast, by Application, 2017-2031
        12.3.1. Heart Failure
        12.3.2. Myocardial Infarction
        12.3.3. Critical Limb Ischemia
        12.3.4. Others
    12.4. Market Value Forecast, by Source, 2017-2031
        12.4.1. Autologous
        12.4.2. Allogenic
    12.5. Market Value Forecast, by End-user, 2017-2031
        12.5.1. Pharmaceutical & Biotechnology Companies
        12.5.2. Hospitals & Cell Banks
        12.5.3. Academic & Research Institutes
    12.6. Market Value Forecast, by Country/Sub-region, 2017-2031
        12.6.1. Germany
        12.6.2. U.K.
        12.6.3. France
        12.6.4. Italy
        12.6.5. Spain
        12.6.6. Rest of Europe
    12.7. Market Attractiveness Analysis
        12.7.1. By Type of Cell
        12.7.2. By Application
        12.7.3. By Source
        12.7.4. By End-user
        12.7.5. By Country/Sub-region
13. Asia Pacific Cardiology Stem Cells Market Analysis and Forecast
    13.1. Introduction
        13.1.1. Key Findings
    13.2. Market Value Forecast, by Type of Cell, 2017-2031
        13.2.1. Embryonic Stem Cells
        13.2.2. Adult Stem Cells
        13.2.3. Induced Pluripotent Stem Cells
        13.2.4. Cord Blood Stem Cells and Amniotic Fluid Stem Cells
    13.3. Market Value Forecast, by Application, 2017-2031
        13.3.1. Heart Failure
        13.3.2. Myocardial Infarction
        13.3.3. Critical Limb Ischemia
        13.3.4. Others
    13.4. Market Value Forecast, by Source, 2017-2031
        13.4.1. Autologous
        13.4.2. Allogenic
    13.5. Market Value Forecast, by End-user, 2017-2031
        13.5.1. Pharmaceutical & Biotechnology Companies
        13.5.2. Hospitals & Cell Banks
        13.5.3. Academic & Research Institutes
    13.6. Market Value Forecast, by Country/Sub-region, 2017-2031
        13.6.1. Japan
        13.6.2. China
        13.6.3. India
        13.6.4. Australia & New Zealand
        13.6.5. Rest of Asia Pacific
    13.7. Market Attractiveness Analysis
        13.7.1. By Type of Cell
        13.7.2. By Application
        13.7.3. By Source
        13.7.4. By End-user
        13.7.5. By Country/Sub-region
14. Latin America Cardiology Stem Cells Market Analysis and Forecast
    14.1. Introduction
        14.1.1. Key Findings
    14.2. Market Value Forecast, by Type of Cell, 2017-2031
        14.2.1. Embryonic Stem Cells
        14.2.2. Adult Stem Cells
        14.2.3. Induced Pluripotent Stem Cells
        14.2.4. Cord Blood Stem Cells and Amniotic Fluid Stem Cells
    14.3. Market Value Forecast, by Application, 2017-2031
        14.3.1. Heart Failure
        14.3.2. Myocardial Infarction
        14.3.3. Critical Limb Ischemia
        14.3.4. Others
    14.4. Market Value Forecast, by Source, 2017-2031
        14.4.1. Autologous
        14.4.2. Allogenic
    14.5. Market Value Forecast, by End-user, 2017-2031
        14.5.1. Pharmaceutical & Biotechnology Companies
        14.5.2. Hospitals & Cell Banks
        14.5.3. Academic & Research Institutes
    14.6. Market Value Forecast, by Country/Sub-region, 2017-2031
        14.6.1. Brazil
        14.6.2. Mexico
        14.6.3. Rest of Latin America
    14.7. Market Attractiveness Analysis
        14.7.1. By Type of Cell
        14.7.2. By Application
        14.7.3. By Source
        14.7.4. By End-user
        14.7.5. By Country/Sub-region
15. Middle East & Africa Cardiology Stem Cells Market Analysis and Forecast
    15.1. Introduction
        15.1.1. Key Findings
    15.2. Market Value Forecast, by Type of Cell, 2017-2031
        15.2.1. Embryonic Stem Cells
        15.2.2. Adult Stem Cells
        15.2.3. Induced Pluripotent Stem Cells
        15.2.4. Cord Blood Stem Cells and Amniotic Fluid Stem Cells
    15.3. Market Value Forecast, by Application, 2017-2031
        15.3.1. Heart Failure
        15.3.2. Myocardial Infarction
        15.3.3. Critical Limb Ischemia
        15.3.4. Others
    15.4. Market Value Forecast, by Source, 2017-2031
        15.4.1. Autologous
        15.4.2. Allogenic
    15.5. Market Value Forecast, by End-user, 2017-2031
        15.5.1. Pharmaceutical & Biotechnology Companies
        15.5.2. Hospitals & Cell Banks
        15.5.3. Academic & Research Institutes
    15.6. Market Value Forecast, by Country/Sub-region, 2017-2031
        15.6.1. GCC Countries
        15.6.2. South Africa
        15.6.3. Rest of Middle East & Africa
    15.7. Market Attractiveness Analysis
        15.7.1. By Type of Cell
        15.7.2. By Application
        15.7.3. By Source
        15.7.4. By End-user
        15.7.5. By Country/Sub-region
16. Competition Landscape
    16.1. Market Player – Competition Matrix (By Tier and Size of companies)
    16.2. Market Share Analysis By Company (2022)
    16.3. Company Profiles
        16.3.1. Astellas Pharma, Inc.
            16.3.1.1. Company Overview
            16.3.1.2. Product Portfolio
            16.3.1.3. SWOT Analysis
            16.3.1.4. Strategic Overview
        16.3.2. STEMCELL Technologies
            16.3.2.1. Company Overview
            16.3.2.2. Product Portfolio
            16.3.2.3. SWOT Analysis
            16.3.2.4. Strategic Overview
        16.3.3. Cellular Engineering Technologies
            16.3.3.1. Company Overview
            16.3.3.2. Product Portfolio
            16.3.3.3. SWOT Analysis
            16.3.3.4. Strategic Overview
        16.3.4. BioTimes, Inc.
            16.3.4.1. Company Overview
            16.3.4.2. Product Portfolio
            16.3.4.3. SWOT Analysis
            16.3.4.4. Strategic Overview
        16.3.5. Takara Bio, Inc.
            16.3.5.1. Company Overview
            16.3.5.2. Product Portfolio
            16.3.5.3. SWOT Analysis
            16.3.5.4. Strategic Overview
        16.3.6. U.S. Stem Cell, Inc.
            16.3.6.1. Company Overview
            16.3.6.2. Product Portfolio
            16.3.6.3. SWOT Analysis
            16.3.6.4. Strategic Overview
        16.3.7. BrainStorm Cell Limited
            16.3.7.1. Company Overview
            16.3.7.2. Product Portfolio
            16.3.7.3. SWOT Analysis
            16.3.7.4. Strategic Overview
        16.3.8. Cytori Therapeutics, Inc.
            16.3.8.1. Company Overview
            16.3.8.2. Product Portfolio
            16.3.8.3. SWOT Analysis
            16.3.8.4. Strategic Overview
        16.3.9. Bio Cardia, Inc.
            16.3.9.1. Company Overview
            16.3.9.2. Product Portfolio
            16.3.9.3. SWOT Analysis
            16.3.9.4. Strategic Overview

List of Tables

Table 01: Global Cardiology Stem Cells Market Value (US$ Bn) Forecast, by Type of Cell, 2017‒2031

Table 02: Global Cardiology Stem Cells Market Value (US$ Bn) Forecast, by Application, 2017‒2031

Table 03: Global Cardiology Stem Cells Market Value (US$ Bn) Forecast, by Source, 2017‒2031

Table 04: Global Cardiology Stem Cells Market Value (US$ Bn) Forecast, by End-user, 2017–2031

Table 05: Global Cardiology Stem Cells Market Value (US$ Bn) Forecast, by Region, 2017–2031

Table 06: North America Cardiology Stem Cells Market Value (US$ Bn) Forecast, by Country, 2017–2031

Table 07: North America Cardiology Stem Cells Market Value (US$ Bn) Forecast, by Type of Cell, 2017‒2031

Table 08: North America Cardiology Stem Cells Market Value (US$ Bn) Forecast, by Application, 2017‒2031

Table 09: North America Cardiology Stem Cells Market Value (US$ Bn) Forecast, by Source, 2017‒2031

Table 10: North America Cardiology Stem Cells Market Value (US$ Bn) Forecast, by End-user, 2017–2031

Table 11: Europe Cardiology Stem Cells Market Value (US$ Bn) Forecast, by Country/Sub-Region, 2017–2031

Table 12: Europe Cardiology Stem Cells Market Value (US$ Bn) Forecast, by Type of Cell, 2017‒2031

Table 13: Europe Cardiology Stem Cells Market Value (US$ Bn) Forecast, by Application, 2017‒2031

Table 14: Europe Cardiology Stem Cells Market Value (US$ Bn) Forecast, by Source, 2017‒2031

Table 15: Europe Cardiology Stem Cells Market Value (US$ Bn) Forecast, by End-user, 2017–2031

Table 16: Asia Pacific Cardiology Stem Cells Market Value (US$ Bn) Forecast, by Country/Sub-region, 2017–2031

Table 17: Asia Pacific Cardiology Stem Cells Market Value (US$ Bn) Forecast, by Type of Cell, 2017‒2031

Table 18: Asia Pacific Cardiology Stem Cells Market Value (US$ Bn) Forecast, by Application, 2017‒2031

Table 19: Asia Pacific Cardiology Stem Cells Market Value (US$ Bn) Forecast, by Source, 2017‒2031

Table 20: Asia Pacific Cardiology Stem Cells Market Value (US$ Bn) Forecast, by End-user, 2017–2031

Table 21: Latin America Cardiology Stem Cells Market Value (US$ Bn) Forecast, by Country/Sub-region, 2017-2031

Table 22: Latin America Cardiology Stem Cells Market Value (US$ Bn) Forecast, by Type of Cell, 2017‒2031

Table 23: Latin America Cardiology Stem Cells Market Value (US$ Bn) Forecast, by Application, 2017‒2031

Table 24: Latin America Cardiology Stem Cells Market Value (US$ Bn) Forecast, by Source, 2017‒2031

Table 25: Latin America Cardiology Stem Cells Market Value (US$ Bn) Forecast, by End-user, 2017–2031

Table 26: Middle East & Africa Cardiology Stem Cells Market Value (US$ Bn) Forecast, by Country/Sub-region, 2017-2031

Table 27: Middle East & Africa Cardiology Stem Cells Market Value (US$ Bn) Forecast, by Type of Cell, 2017‒2031

Table 28: Middle East & Africa Cardiology Stem Cells Market Value (US$ Bn) Forecast, by Application, 2017‒2031

Table 29: Middle East & Africa Cardiology Stem Cells Market Value (US$ Bn) Forecast, by Source, 2017‒2031

Table 30: Middle East & Africa Cardiology Stem Cells Market Value (US$ Bn) Forecast, by End-user, 2017–2031

❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer
★リサーチレポート[ 心臓幹細胞の世界市場2023～2031：用途別、ソース別(Cardiology Stem Cells Market (Application: Heart Failure, Myocardial Infarction, Critical Limb Ischemia, and Others; Source: Autologous and Allogenic) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031)]についてメールでお問い合わせはこちらでお願いします。
◆関連リサーチレポート◆
  • 単球活性化試験の世界市場2023～2031：製品種類別、ソース別
  • 細胞治療技術の世界市場2022～2031：細胞種類別、用途別
  • 同種幹細胞の世界市場2023～2031：種類別、細胞源別、用途別、エンドユーザー別、地域別
  • 間葉系幹細胞の世界市場2023～2031：製品・サービス別、分離源別

    • ◆H&Iグローバルリサーチのお客様（例）◆